Merck Over the course of its 350-year history, Merck KGaA has expanded from its base in Darmstadt, Germany to establish a strong presence in various markets across the globe. Last year, PharmaBoardroom spoke with Merck affiliate leaders in multiple geographies, uncovering their concerns and priorities as the firm pushed to recover…

Portugal Women account for half of the Portuguese labour force, but Portugal lags behind the European average for women in top positions, as a 2023 McKinsey study shows. However, Portuguese pharma appears to buck this trend, with several women assuming leadership positions within the country. Indeed, over half of the 13…

Portugal Diabetes is a rising threat to the Portuguese people, the country’s healthcare system, and its economy. Portugal’s National Diabetes Observatory observed that 1.1 million Portuguese people between the ages of 20 and 79.5 (out of a total population of just 10.3 million) were living with diabetes in 2021.   This…

Portugal Novo Nordisk’s spectacular ascendancy in 2023 has meant that its country managers across the world have had to embrace scrutiny and press coverage like never before.   In its centenary year, the Danish firm’s new generation of obesity drugs supercharged revenues to around EUR 30 billion, a 30 percent hike…

Portugal While not a major player in clinical trials at the European level, Portugal has untapped potential in this field, leveraging a first pioneering centre in Braga, the country’s strong scientific community, a growing openness to collaboration with industry, and access to a European patient database. Considering the remarkable progress that…

Portugal Portugal boasts a well-developed universal healthcare system and saw healthcare spending increase by 6.2 percent annually between 2016 and 2021, according to the OECD. However, the representatives of innovative medicines manufacturers embedded in the country are keen to point out that access to the latest drugs remains a big issue…

Portugal Portugal’s strong legal framework along with its low production costs and strategic location within Europe have given rise to a thriving medicinal cannabis sector. With exports in 2022 that surpassed the previous year by 63 percent and an increasing number of companies licensed for cultivation and manufacturing, the country is…

Portugal One of Europe’s smaller nations and its westernmost, Portugal, with a pharma market worth roughly USD 3.5 billion, may not be known as the continent’s pharma powerhouse. Yet the country boasts plenty of impressive credentials —such as a national healthcare system (NHS) that is not only universal and free, but…

Portugal Lawyer Joana Silveira Botelho provides regular legal assistance to pharmaceutical companies and other entities of the health sector. Here she examines Portugal’s new regulatory framework on cannabis for medicinal purposes.    What will actually change considering that in Portugal (and in the European Union) it is already possible to obtain a marketing…

R&D Portugal has forged a name for itself in terms of early adoption of new technology and ideas; making the country a prime destination for clinical trials as well as a market in which multinational pharma companies can trial innovative new treatments before rolling them out across the continent. “We are…

Portugal Similar to many Western economies, Portugal is attempting to embrace digitalization in healthcare, but unlike Europe’s Big Five which struggle due to huge populations and decentralized systems, thanks to Portugal’s size and tech-savvy population, industry players and authorities have found success in implementing nationwide digital projects. “We benefit from a…

Portugal A new regulation is helping Portugal’s market access conditions for pharmaceuticals catch up with those of other developed European markets, with a jump in the number of approvals for 2017. The situation is further enhanced by increasing inter-stakeholder communication and transparency, and a targeted focus on removing bureaucracy barriers, from…